Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07797218 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a randomized, open-label, superiority, multicenter clinical trial for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer. It aims to compare the efficacy of neoadjuvant treatment with 2 cycles of Pyrotinib + Trastuzumab + Docetaxel followed by 2 cycles of Pertuzumab + Trastuzumab + Docetaxel versus 4 cycles of Pertuzumab + Trastuzumab + Docetaxel. Exploratory analyses of ctDNA clearance rate and MRI response will also be conducted.
Trial Details
NCT Number NCT07797218
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions
(from sponsor)		 Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Related terms Breast Neoplasms
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov